<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057482</url>
  </required_header>
  <id_info>
    <org_study_id>2050</org_study_id>
    <nct_id>NCT04057482</nct_id>
  </id_info>
  <brief_title>Treatment of BV With Donaxyl and a Molecular Test of Cure</brief_title>
  <official_title>Treatment of Bacterial Vaginosis With Dequalinium Chloride Vaginal Tablets and a Test of Cure Using a New Molecular Diagnostic Test for the Diagnosis of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skaraborg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Skaraborg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      . Treatment with dequalinium chloride vaginal tablets for 6 days had a cure rate lower than
      expected; only 37% of patients were considered cured one month after treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first study to utilize a molecular diagnostic test as a test of cure for
      bacterial vaginosis. The Nugent score is a reliable method for diagnosing bacterial
      vaginosis, but similar to traditional clinical diagnostic methods, it is not equally reliable
      when utilized as a test of cure. This study demonstrated that molecular diagnostic testing
      can be used as a test of cure and this is the first molecular test that can do that.
      Treatment with dequalinium chloride vaginal tablets for 6 days had a cure rate lower than
      expected; only 37% of patients were considered cured one month after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cure rate of BV</measure>
    <time_frame>1 year</time_frame>
    <description>how many that are cured of BV after 1 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of BV using molecular test</measure>
    <time_frame>1 year</time_frame>
    <description>the Kappa index Hay/ison diagnosis and the molecular test</description>
  </secondary_outcome>
  <enrollment type="Actual">58</enrollment>
  <condition>Bacterial Vaginoses</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D</intervention_name>
    <description>treatment of BV with dequalinium chloride vaginal tablets</description>
    <other_name>dequalinium chloride vaginal tablets</other_name>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Molecu
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        local maternity and youth clinics in Skaraborg county
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        BV

        Exclusion Criteria:

        No other infection (Gc, clhlamydia, trihomonas)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P-G Larsson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>överläkare</affiliation>
  </overall_official>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skaraborg Hospital</investigator_affiliation>
    <investigator_full_name>Per-Goran Larsson</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Bacterial vaginosis, polymerase chain reaction, molecular diagnostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dequalinium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

